Oral solution to diabetes

New insights into the mode of action thiazolidinediones (TZDs) class of oral pharmaceuticals for type 2 diabetes are revealed this month in the journal Diabetes. Allison Goldfine and colleagues at the Joslin Diabetes Center in Boston examined muscle and fat tissue from patients with type 2 diabetes before and after they took the TZD drug rosiglitazone. The researchers found that levels of two proteins, Necdin and E2F4, which are important in regulating cell replication, were altered in muscle and fat after two months. “Because the proteins are important in regulating the cell cycle, the findings suggest that TZDs may work, in part, by altering the cell differentiation state, or level of cell maturity. Additionally, the two proteins Necdin and E2F4 may represent new drug targets that may be useful in the future for treatment of patients with diabetes, says Goldfine.